INKT
MiNK Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.48
−3.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 154.3K | 181.7K | 215.4K | 204.6K | 121.7K |
| Gross Profit | (154.3K) | (181.7K) | (215.4K) | (204.6K) | (121.7K) |
| Operating Expenses | |||||
| R&D Expense | 5.7M | 5.8M | 6.3M | 15.5M | 23.1M |
| SG&A Expense | 6.5M | 6.5M | 4.1M | 7.4M | 7.7M |
| General & Admin Expense | 1.3M | — | 4.3B | 7.4M | — |
| Selling & Marketing Expense | — | — | (4.3B) | — | — |
| Other Expenses | (36.1K) | — | — | (204.6K) | — |
| Total Operating Expenses | 12.2M | 12.3M | 10.4M | 22.7M | 30.8M |
| Cost and Expenses | 12.4M | 12.5M | 10.7M | 22.9M | 30.9M |
| Operating Income (EBIT) | (12.4M) | (12.5M) | (10.7M) | (22.9M) | (30.9M) |
| Non-Operating | |||||
| Interest Income | 139.9K | 180.2K | 172.6K | 463.3K | 253.3K |
| Interest Expense | — | — | — | — | 253.3K |
| Net Interest Income | 139.9K | 180.2K | 172.6K | 463.3K | — |
| Other Non-Op Income/Expense | 1.0M | (7.0K) | (134.6K) | 463.2K | 3.0M |
| Non-Operating Income (excl Interest) | (225.6K) | — | 134.6K | (463.2K) | (3.0M) |
| EBT (Pre-Tax Income) | (11.4M) | (12.5M) | (10.8M) | (22.5M) | (28.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (11.4M) | (12.5M) | (10.8M) | (22.5M) | (28.0M) |
| Earnings from Cont. Ops | (11.4M) | (12.5M) | (10.8M) | (22.5M) | (28.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.4M) | (12.5M) | (10.8M) | (22.5M) | (28.0M) |
| Per Share | |||||
| Basic EPS | ($2.39) | ($2.93) | ($2.90) | ($6.54) | ($8.31) |
| Diluted EPS | ($2.39) | ($2.93) | ($2.80) | ($6.54) | ($8.31) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.0M | 4.3M | 3.7M | 3.4M | 3.4M |
| Diluted Shares Outstanding | 5.0M | 4.3M | 3.9M | 3.4M | 3.4M |
| Profitability Metrics | |||||
| EBITDA | (12.0M) | (12.3M) | (10.6M) | (22.3M) | (27.9M) |
| D&A | 154.3K | 181.7K | 215.4K | 204.6K | 121.7K |
| EBIT | (12.1M) | (12.5M) | (10.8M) | (22.5M) | (28.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026